Global Think-tank on Steatotic Liver Disease 2025 meeting
- PMID: 40635802
- PMCID: PMC12240081
- DOI: 10.1016/j.lanepe.2025.101366
Global Think-tank on Steatotic Liver Disease 2025 meeting
Conflict of interest statement
JVL acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, Moderna, MSD, Novo Nordisk, Pfizer, and Roche Diagnostics, consulting fees from Echosens, GSK, Novavax, Novo Nordisk, Pfizer, and Prosciento, and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer, outside of this work. PNB acknowledges consulting fees, payment or honoraria, and support for attending meetings and/or travel from Novo Nordisk and Resolution Therapeutics, outside of this work. SI declares no competing interests. MT received speaker’s fee from Echosens, Madrigal, Takeda, and Novo Nordisk. Advisory fee from Boehringer Ingelheim, Astra Zeneca, Novo Nordisk and GSK. Research grant from GSK and is a Co-founder of Evido.
References
-
- Global think-tank on steatotic liver disease. https://sldthinktank.com/about/ [cited 2025 Jun 11] Available from:
-
- Lazarus J.V., Brennan P.N., Mark H.E., et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. Lancet Reg Health Eur. 2025 https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00112... [cited 2025 Jun 11];101320–0. Available from:
-
- Lazarus J.V., Wajcman D.I., Pannain S., et al. The people-first liver charter. Nat Med. 2025 https://www.nature.com/articles/s41591-025-03759-8 [cited 2025 Jun 11]; Available from: - PubMed
LinkOut - more resources
Full Text Sources
